ArticleBMC neurology2026
Continuous intracerebroventricular morphine infusion for intractable neuropathic pain.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis study aimed to explore the effectiveness and safety of continuous intracerebroventricular (ICV) morphine infusion for intractable pathological pain in the head, face, and upper limbs using the SynchroMed II intrathecal drug infusion system.
methodsThe clinical data of eight patients with intractable pathological pain in the head, face, and upper limbs who were treated with ICV morphine infused using the SynchroMed II system were analyzed. The numeric rating scale (NRS) was used to evaluate the degree of pain. NRS change, morphine dose, and its side effects and complications were the main observation indicators.
resultsThe average pain amelioration was 60.68% ± 15.40%. Furthermore, the Pre-op NRS was 9.000 ± 1.309; the Optimum NRS (Op-NRS)was 2.000 ± 1.414; and the last NRS(L-NRS)was 3.500 ± 1.414. The Preoperative NRS (Pre-op NRS)was significantly higher than the Op-NRS (t = 7.329, P<0.0001) and L-NRS (t = 8.072, P < 0.0001), whereas the Op-NRS and L-NRS showed no significant difference (t = 2.121, P = 0.0522). The mean initial dose was 212.5 ± 35.36 (range, 200–300) mcg/24 h; individual optimal dose, 445.0 ± 93.04 (range, 350–650) mcg/24 h; and final dose, 560.0 ± 256.0 (range, 350–1100) mcg/24 h. The side effects included nausea and vomiting, dizziness, and visual hallucinations. Transient urinary retention is a common side effect of drug dosage adjustment. All the patients without infection and cerebral hemorrhage and other complications.
conclusionICV morphine infusion using the SynchroMed II system is safe and effective for intractable pathological pain in the head, face, and upper limbs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.